Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 191 of the 198 references it cites were found in a registry or an index; 135 of the 193 sources its claims cite were checked for support.

Mycobacterium smegmatis: The Vanguard of Mycobacterial Research

Open access

Abstract

155 have since provided previously unattainable insights on these same features in its slow-growing relatives. Notably, tuberculosis (TB) drugs, including the first-line drugs isoniazid and ethambutol, are active against M. smegmatis, but not against E. coli, allowing the identification of their physiological targets. Furthermore, Bedaquiline, the first new TB drug in 40 years, was discovered through an M. smegmatis screen. M. smegmatis has become a model bacterium, not only for M. tuberculosis, but for all other Mycobacterium species and related genera. With a repertoire of bioinformatic and physical resources, including the recently established Mycobacterial Systems Resource, M. smegmatis will continue to accelerate mycobacterial research and advance the field of microbiology.

Overview

CoChat Summary

TL;DR

This review argues that *Mycobacterium smegmatis* mc²155, a fast-growing nonpathogenic mycobacterium isolated in 1990 as a plasmid-transformable mutant, has become the foundational model organism for mycobacterial research, including tuberculosis. It traces the strain's history, the genetic tools and community resources built on it, and the discoveries in conjugation, gene architecture, cell envelope biology, and drug mechanism/target identification that it enabled.

Key findings

  • mc²155 arose from a rare transformant of *M. smegmatis* mc²6 that had acquired an efficient plasmid transformation (ept-1) phenotype, routinely yielding up to a million transformants per microgram of plasmid DNA; the mutation was later mapped to *eptC*, encoding a structural-maintenance-of-the-chromosome (SMC) protein.
  • Comparative genomics support the model: of ~4,000 *M. tuberculosis* protein-coding genes, >2,800 have orthologs in *M. smegmatis* with >50% amino acid identity; a conservative core of ~1,150 *M. smegmatis* proteins share >50% identity across MTBC, *M. abscessus*, *M. marinum*, *M. avium*, and *M. leprae*; 96% of genes essential in *M. smegmatis* have *M. tuberculosis* orthologs, 90% of which are essential in *M. tuberculosis*.
  • The Mycobacterial Systems Resource (MSR) provides 569 precise knockouts of non-essential genes, CRISPRi plasmids targeting 843 genes, and 1,116 Dendra2-tagged fusion constructs; a spatiotemporal analysis of over 700 proteins and a CRISPRi morphological atlas of 263 essential genes both showed that subcellular localization and morphotype cluster with biological function.
  • *M. smegmatis* work established distributive conjugal transfer (DCT) as a novel HGT mechanism producing mosaic progeny genomes, implicated ESX-4 in contact-dependent cell-cell communication, revealed abundant leaderless mRNAs (25–30% of mycobacterial mRNAs; 1,285 in *M. tuberculosis*, of which 338 were mis-annotated and 370 unannotated), and underpinned drug work: INH activation by KatG and InhA as its target, EMB's inhibition of EmbA/EmbB arabinosyltransferases, and the initial screen identifying Bedaquiline (diarylquinoline) as an ATP synthase inhibitor.

Methods

  • Narrative review synthesizing three decades of published literature on *M. smegmatis* mc²155; no primary experimental data are reported.
  • Covers the strain's isolation history, genetic tool development, comparative genomics, community bioinformatic and physical resources (Mycobrowser, BioCyc, MSRdb, Wadsworth Interactive Genomics), and selected discoveries in HGT, gene architecture, secretion, cell envelope biology, and drug discovery.
  • The authors also state a position against renaming *M. smegmatis* as *Mycolicibacterium smegmatis*, citing the Tortoli et al. editorial.

Limitations

  • Stated by the paper: *M. smegmatis* is more distantly related to slow-growing species and is a poor model for host-pathogen interactions and pathogenesis; *M. bovis* BCG and *M. marinum* are offered as BSL-2 alternatives, though BCG has a complex genealogy with lineage-specific mutations, and in vivo pathogenesis work ultimately requires virulent strains and models such as the *M. tuberculosis*-mouse and *M. marinum*-zebrafish systems.
  • Evident from the text: as a narrative review, it is explicitly selective — the authors acknowledge "countless other remarkable contributions" excluded due to space limitations — and it presents no systematic search strategy or quantitative synthesis.
  • Evident from the text: the authors are themselves central contributors to much of the work reviewed (mc²155 isolation, MSR, DCT, leaderless mRNA studies), and the anti-renaming stance is an advocacy position rather than a finding.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1128/jb.00337-22

Cites

191 of 191 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

79 Valid · 9 Not valid · 26 Not checked · 26 Own results and interpretations

64 more claims · 38 with their cited sources checked

Create a free account to see all 140 claims and every source verdict.

See all claims — free account
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • It may state two separate claims as one. 49
  • Not yet classified. 6
  • Probably not a substantial claim. 27

Create a free account to see these claims.

Citations

Cites

Show all 198 references

Research works printed but not linked: 2

  1. Koch R. 1882. Die Aetiologie der Tuberculose. (Nach einem in der physiologischen Gesellschaft zu Berlin am 24.März cr. gehaltenem Vortrage). Berliner Klin Wochenschr 19:221–230.
  2. Minnikin DE. 1982. Lipids: complex lipids, their chemistry, biosynthesis and role, p 95–184. In The biology of mycobacteria. Academic Press, London, UK.

Cited by

See all 149

Metadata

Authors
Sparks, I. L., Derbyshire, K. M., Jacobs, W. R., & Morita, Y. S.
Affiliations
  • University of Massachusetts Amherst (US)
  • New York State Department of Health (US)
  • Albert Einstein College of Medicine (US)
Corresponding author
Morita, Yasu S.
Venue
Journal of Bacteriology
Published
2023-01-26
Volume
205
Issue
1
Pages
e0033722-e0033722
ISSN
  • 0021-9193 (ISSN-L)
  • 1098-5530
OpenAlex
W4313487963
Cited by
149
References
198
Citations by year
2026: 47 · 2025: 60 · 2024: 29 · 2023: 13
FWCI
7.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Bacteriology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
HHS | National Institutes of Health (R21 AI144748, R21 AI14760802, R01 GM13927703, R01 AI026170)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
Keywords
Mycobacterium smegmatis, Mycobacterium tuberculosis, tuberculosis drug discovery, isoniazid, ethambutol, bedaquiline, drug target identification, model organisms
MeSH terms
Escherichia coli, Humans, Isoniazid, Mycobacterium tuberculosis, Tuberculosis, Mycobacterium smegmatis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mycobacterium smegmatis: The Vanguard of Mycobacterial Research. https://app.cochat.ai/papers/10.1128/jb.00337-22
The paper
Sparks, I. L., Derbyshire, K. M., Jacobs, W. R., & Morita, Y. S. (2023). Mycobacterium smegmatis: The Vanguard of Mycobacterial Research. Journal of Bacteriology. https://doi.org/10.1128/jb.00337-22

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.